



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Date: 2nd November, 2021

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Security Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 2nd November, 2021

Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 2nd November, 2021 have

1. Approved the Unaudited Financial Results of the Company for the quarter and half-year ended on 30th September, 2021.

We enclose herewith the Limited Review Report of the Unaudited Financial Results of the Company for the quarter and half-year ended on 30th September, 2021 issued by the Statutory Auditors of the Company.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited


Srushti Pandya
Company Secretary and Compliance Officer



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



Date: 02/11/2021

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 July 2021 to 30 Sep 2021** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES

Chartered Accountants

CA Mayank Sancheti
M No. :170863
Date: 02/11/2021
Place: Ahmedabad
UDIN: 21170863AAAAEC7988

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2021

Amount in Lacs except Per Share data

Particulars	Quarter Ended			Half Year Ended		Year Ended
	3 Months Ended	3 Months Ended	3 Months Ended	6 Months Ended	6 Months Ended	12 Months Ended
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
1 INCOME						
Revenue from Operations	289.607	288.928	379.629	578.535	610.030	1394.901
Other Income	5.032	3.798	3.683	8.830	4.063	31.357
Total Income	294.639	292.726	383.312	587.365	614.093	1426.258
2 EXPENSES						
(a) Cost of Material Consumed	201.669	197.651	303.691	399.320	457.607	956.397
(b) Purchase of Stock-In-Trade	5.950	2.900	0.000	8.850	1.469	63.183
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-6.006	-4.651	-9.285	-10.657	-11.882	9.130
(d) Employee Benefit Expense	27.149	26.958	25.902	54.107	51.513	109.743
(e) Finance Cost	1.247	0.451	0.618	1.698	1.185	3.163
(f) Depreciation, Depletion and Amortisation Expense	3.653	3.654	4.436	7.307	8.873	14.614
(g) Other Expense	43.054	48.151	38.814	91.205	74.130	164.654
Total Other Expenses	43.054	48.151	38.814	91.205	74.130	164.654
Total Expenses	276.716	275.114	364.176	551.830	582.895	1320.884
3 Total Profit before Exceptional Items and Tax	17.923	17.612	19.137	35.535	31.198	105.374
4 Exceptional Items	0.000	0.000	0.000	0.000	0.000	0.000
5 Total Profit before Tax	17.923	17.612	19.137	35.535	31.198	105.374
6 Tax Expense						
7 Current Tax	4.000	4.000	4.000	8.000	7.000	23.000
8 Deferred Tax	0.000	0.000	0.000	0.000	0.000	-0.580
9 Total Tax Expenses	4.000	4.000	4.000	8.000	7.000	22.420
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000	0.000	0.000
11 Net Profit Loss for the period from continuing operations	13.923	13.612	15.137	27.535	24.198	82.954
12 Profit / (Loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
13 Tax Expenses of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
14 Net Profit / (Loss) from discontinued operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000
16 Total Profit / (Loss) for the period	13.923	13.612	15.137	27.535	24.198	82.954
17 Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000	0.000	0.000
18 Total Comprehensive Income for the Period	13.923	13.612	15.137	27.535	24.198	82.954

Jaydin Agrawal

19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.000	0.000	0.000	0.000	0.000	0.000
	Total Profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
20	Total comprehensive income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of parents	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.030	299.030	299.030	299.030	299.030	299.030
	Face Value of Equity Share Capital	10.000	10.000	10.000	10.000	10.000	10.000
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.000	0.000	0.000	0.000	0.000	0.000
	Face Value of Debt Securities	0.000	0.000	0.000	0.000	0.000	0.000
23	Reserves Excluding Revaluation Reserves	0.000	0.000	0.000	0.000	0.000	0.000
24	Debenture Redemption Reserve	0.000	0.000	0.000	0.000	0.000	0.000
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.466	0.455	0.506	0.921	0.809	2.774
	Diluted Earnings / (Loss) per share from continuing operations	0.466	0.455	0.506	0.921	0.809	2.774
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
	Diluted Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.466	0.455	0.506	0.921	0.809	2.774
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.466	0.455	0.506	0.921	0.809	2.774
26	Debt Equity Ratio	--	--	--	--	--	--
27	Debt Service Coverage Ratio	--	--	--	--	--	--
28	Interest Service Coverage Ratio	--	--	--	--	--	--

Agreed and approved

NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 02, 2021.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2021 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED****JAGDISH AGRAWAL****MANAGING DIRECTOR**Place **Ahmedabad**Date **02-Nov-21****DIN: 01031687**

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com


Contact: +91 7226995613/14/15

Statement of Assets and Liabilities

Amount in Lakhs

	Particulars	Half Year Ended	Previous Year Ended
		6 Months Ended	12 Months Ended
		Unaudited	Audited
		30-Sep-21	31-Mar-21
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	92.268	99.580
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	92.268	99.580
	Non-current investments	26.858	22.590
	Trade receivables, non-current		
	Loans, non-current		
	Other non-current financial assets	13.924	5.070
	Total Non-current financial assets	40.782	27.660
	Deferred tax assets (net)		
	Other non-current assets		
	Total Non-current Assets	133.050	127.240
2	Current assets		
	Inventories	60.624	65.440
	Current financial assets		
	Current investments	303.499	288.500
	Trade receivables, current	107.055	152.380
	Cash and cash equivalents	287.220	175.320
	Bank balance other than cash and cash equivalent	138.511	78.510
	Loans, current	2.000	36.470
	Other current financial assets	0.369	2.630
	Total current financial assets	838.653	733.810
	Current tax assets (net)		
	Other current assets		
	Total Current Assets		
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	TOTAL ASSETS	1032.327	926.490

Signature

	EQUITIES AND LIABILITIES		
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	299.030	299.030
	Other equity	507.573	480.040
	Total Equity attributable to owners of Parent	806.603	779.070
	Non controlling interest		
	Total Equity	806.603	779.070
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	0.000	0.000
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	0.000	0.000
	Provisions, non-current		
	Deferred tax liabilities (net)	4.109	4.110
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	4.109	4.110
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	98.392	0.000
	Trade payables, current	73.067	98.240
	Other current financial liabilities	2.145	4.190
	Total current financial liabilities	173.605	102.430
	Other current liabilities	10.633	10.910
	Provisions, current	19.219	7.660
	Current tax liabilities (Net)	18.159	22.310
	Deferred government grants, Current		
	Total current liabilities	48.010	40.880
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities		
	Total Equity and Liabilities	1032.327	926.490
For, ISHITA DRUGS AND INDUSTRIES LIMITED			
			
JAGDISH AGRAWAL			
Place	Ahmedabad	MANAGING DIRECTOR	
Date	02-Nov-21	DIN: 01031687	

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

**Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170**

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

AUDITED CASH FLOW STATEMENT

Sr. No.	Perticulers	Unaudited Halfyear Ended 30.09.2021 Rs. In Lakhs	Audited Year Ended 31.03.2021 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	35.535	105.370
	Add : Depreciation	7.307	14.610
	Interest & Other financial charges	1.698	3.160
	Loss on sale of fixed assets	0.000	0.000
	Less : Interest received	2.000	4.030
	Dividend received	0.009	0.010
	Income from Investments	2.255	27.310
	Operating profit before change in working capital	40.276	91.790
	Add : Trade Debtors	45.323	(21.280)
	Decrease/(Increase) in Inventory	4.819	(7.350)
	Decrease/(Increase) in Loans and advances	27.883	(21.830)
	Less : Provision for Taxation	8.000	23.000
	Decrease/(Increase) Shore Term Provision	(11.281)	(1.880)
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	29.324	87.690
	Net cash generated from operating activities (A)	92.257	(67.480)
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	(19.270)	218.260
	Dividend received	0.009	0.010
	Income from Investments	2.255	27.310
	Less : Investment in fixed assets	(0.002)	0.490
	Net cash generated from investing activities (B)	(17.004)	245.090
(C)	Cash flow from financial activities :		
	Add : Interest received	2.000	4.030
	Borrowings	96.343	(24.610)
	Less : Interest & Other financial charges	1.698	3.160
	Net cash generated from financial activities (C)	96.645	(23.740)
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	171.898	153.870
	Opening balance of Cash and cash equivalents	253.833	99.960
	Closing balance of Cash and cash equivalents	425.730	253.830
	Net Increase/(decrease) in Cash & Cash Equivalents	171.898	153.870

Note : Figures in bracket indicate negative value
Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal

JAGDISH AGRAWAL

Place	Ahmedabad	MANAGING DIRECTOR
Date	02-Nov-21	DIN: 01031687